Enhancement of endocannabinoid signalling during adolescence: Modulation of impulsivity and long-term consequences on metabolic brain parameters in early maternally deprived rats

Pharmacology Biochemistry and Behavior

Volumn 86, Issue 2, 2007, Pages 334-345

  Marco, Eva María ^a,b   Adriani, Walter ^a   Canese, Rossella ^a   Podo, Franca ^a   Viveros, Maria Paz ^b   Laviola, Giovanni ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Adolescence; Cannabinoid drugs; Fatty acid amide hydrolase (FAAH); Intolerance to delay; Magnetic resonance spectroscopy (MRS); Maternal deprivation; Rat; URB597

Indexed keywords

CREATINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE INHIBITOR; GLUTAMIC ACID; GLUTAMINE; N ACETYLASPARTIC ACID;

ANIMAL EXPERIMENT; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DOWN REGULATION; HIPPOCAMPUS; IMPULSIVENESS; LOCOMOTION; MALE; MATERNAL DEPRIVATION; NEUROCHEMISTRY; NEUROMODULATION; NEUROPSYCHIATRY; NONHUMAN; PERINATAL PERIOD; PHENOTYPE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SELF CONTROL; SIGNAL TRANSDUCTION; UPREGULATION;

AMIDOHYDROLASES; ANIMALS; BENZAMIDES; BRAIN; BRAIN CHEMISTRY; CARBAMATES; CONDITIONING, OPERANT; ENDOCANNABINOIDS; ENZYME INHIBITORS; FEMALE; HIPPOCAMPUS; IMPULSIVE BEHAVIOR; MAGNETIC RESONANCE SPECTROSCOPY; MATERNAL DEPRIVATION; MOTOR ACTIVITY; NEOSTRIATUM; NUCLEUS ACCUMBENS; PREGNANCY; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; WEIGHT GAIN;

ANIMALIA; RATTUS;

EID: 33847105146     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.10.006     Document Type: Article

References (90)

1. Adriani W., and Laviola G. Elevated levels of impulsivity and reduced place conditioning with d-amphetamine: two behavioral features of adolescence in mice. Behav Neurosci 117 (2003) 695-703
2. Adriani W., and Laviola G. Windows of vulnerability to psychopathology and therapeutic strategy in the adolescent rodent model. Behav Pharmacol 15 (2004) 341-352
3. Adriani W., Rea M., Baviera M., Invernizzi W., Carli M., Ghirardi O., et al. Acetyl-l-carnitine reduces impulsive behaviour in adolescent rats. Psychopharmacology 176 (2004) 296-304
4. Adriani W., Giannakopoulou D., Bokulic Z., Jernej B., Alleva E., and Laviola G. Response to novelty, social and self-control behaviors, in rats exposed to neonatal anoxia: modulatory effects of an enriched environment. Psychopharmacology 184 (2006) 155-165
5. Alger B.E. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol 68 (2002) 247-286
6. Arguello P.A., and Jentsch J.D. Cannabinoid CB1 receptor-mediated impairment of visuospatial attention in the rat. Psychopharmacology 177 (2004) 141-150
7. Arseneault L., Cannon M., Witton J., and Murray R.M. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184 (2004) 110-117
8. Belue R.C., Howlett A.C., Westlake T.M., and Hutchings D.E. The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicol Teratol 17 (1995) 25-30
9. Bjork J.M., Moeller F.G., Dougherty D.M., Swann A.C., Machado M.A., and Hanis C.L. Serotonin 2a receptor T102C polymorphism and impaired impulse control. Am J Med Genet 114 (2002) 336-339
10. Bruhn H., Frahm J., Gyngell M.L., Merboldt K.D., Hanicke W., and Sauter R. Cerebral metabolism in man after acute stroke: new observations using localized proton NMR spectroscopy. Magn Reson Med 9 (1989) 126-131
11. Calignano A., La Rana G., Giuffrida A., and Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 394 (1998) 277-281
12. Cardinal R.N., Pennicott D.R., Sugathapala C.L., Robbins T.W., and Everitt B.J. Impulsive choice induced in rats by lesions of the nucleus accumbens core. Science 292 (2001) 2499-2501
13. Cardinal R.N., Winstanley C.A., Robbins T.W., and Everitt B.J. Limbic corticostriatal systems and delayed reinforcement. Ann NY Acad Sci 1021 (2004) 33-50
14. Chaperon F., and Thiebot M.H. Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 13 (1999) 243-281
15. Cheung T.H., and Cardinal R.N. Hippocampal lesions facilitate instrumental learning with delayed reinforcement but induce impulsive choice in rats. BMC Neurosci 6 (2005) 36
16. Cirulli F., and Laviola G. Paradoxical effects of d-amphetamine in infant and adolescent mice: role of ender and environmental risk factors. Neurosci Biobehav Rev 24 (2000) 73-84
17. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., and Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 (1996) 83-87
18. Croxford J.L. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17 (2003) 179-202
19. Crystal J.D., Maxwell K.W., and Hohmann A.G. Cannabinoid modulation of sensitivity to time. Behav Brain Res 144 (2003) 57-66
20. Di Marzo V., and Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 8 (2005) 585-589
21. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
22. Di Marzo V., De Petrocellis L., Fezza F., Ligresti A., and Bisogno T. Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 66 (2002) 377-391
23. Ellenbroek B.A., van den Kroonenberg P.T., and Cools A.R. The effects of an early stressful life event on sensorimotor gating in adult rats. Schizophr Res 30 (1998) 251-260
24. Ellenbroek B.A., Derks N., and Park H.J. Early maternal deprivation retards neurodevelopment in Wistar rats. Stress 8 (2005) 247-257
25. Evenden J.L., and Ryan C.N. The pharmacology of impulsive behaviour in rats VI: the effects of ethanol and selective serotonergic drugs on response choice with varying delays of reinforcement. Psychopharmacology 146 (1999) 413-421
26. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313 (2005) 352-358
27. Fowler C.J., Holt S., Nilsson O., Jonsson K.O., Tiger G., and Jacobsson S.O. The endocannabinoid signaling system: pharmacological and therapeutic aspects. Pharmacol Biochem Behav 81 (2005) 248-262
28. Fride E. The endocannabinoid-CB receptor system: importance for development and in pediatric disease. Neuro Endocrinol Lett 25 (2004) 24-30
29. Fride E. Endocannabinoids in the central nervous system: from neuronal networks to behavior. Curr Drug Targets CNS Neurol Disord 4 (2005) 633-642
30. Fride E., Bregman T., and Kirkham T.C. Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. Exp Biol Med 230 (2005) 225-234
31. Fu J., Gaetani S., Oveisi F., Lo Verme J., Serrano A., Rodriguez De Fonseca F., et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425 (2003) 90-93
32. Genn R.F., Tucci S., Marco E.M., Viveros M.P., and File S.E. Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. Pharmacol Biochem Behav 77 (2004) 567-573
33. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 102 (2005) 18620-18625
34. Hájos N., and Freund T.F. Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem Phys Lipids 121 (2002) 73-82
35. Haller J., Varga B., Ledent C., and Freund T.F. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 15 (2004) 299-304
36. Haller J., Szirmai M., Varga B., Ledent C., and Freund T.F. Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behav Pharmacol 16 (2005) 415-422
37. Henriksen O., Gideon P., Sperling B., Olsen T.S., Jorgensen H.S., and Arlien-Soborg P. Cerebral lactate production and blood flow in acute stroke. J Magn Reson Imaging 2 (1992) 511-517
38. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87 (1990) 1932-1936
39. Hill M.N., and Gorzalka B.B. Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress. Eur J Pharmacol 499 (2004) 291-295
40. Hill M.N., Sun J.C., Tse M.T., and Gorzalka B.B. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int J Neuropsychopharmacol 9 (2006) 277-286
41. Ho M.Y., Mobini S., Chiang T.J., Bradshaw C.M., and Szabadi E. Theory and method in the quantitative analysis of "impulsive choice" behaviour: implications for psychopharmacology. Psycho-pharmacology 146 (1999) 362-372
42. Hofer M.A., Brunelli S.A., and Shair H.N. Potentiation of isolation-induced vocalization by brief exposure of rat pups to maternal cues. Dev Psychobiol 27 (1994) 503-517
43. Hollister L.E. Health aspects of cannabis. Pharmacol Rev 38 (1986) 1-20
44. Imamura K., and Proton M.R. spectroscopy of the brain with a focus on chemical issues. Magn Reson Med Sci 2 (2003) 117-132
45. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
46. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S.P., Bai G., et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 115 (2005) 3104-3116
47. Jin K., Xie L., Kim S.H., Parmentier-Batteur S., Sun Y., Mao X.O., et al. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol Pharmacol 66 (2004) 204-208
48. Jonsson K.O., Holt S., and Fowler C.J. The endocannabinoid system: current pharmacological research and therapeutic possibilities. Basic Clin Pharmacol Toxicol 98 (2006) 124-134
49. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9 (2003) 76-81
50. Keevil S.F., Barbiroli B., Brooks J.C., Cady E.B., Canese R., Carlier P., et al. Absolute metabolite quantification by in vivo NMR spectroscopy: II. A multicentre trial of protocols for in vivo localised proton studies of human brain. Magn Reson Imaging 16 (1998) 1093-1106
51. Lambert D.M., and Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic?. Curr Med Chem 6 (1999) 757-773
52. Laviola G., Adriani W., Terranova M.L., and Gerra G. Psychobiological risk factors for vulnerability to psychostimulants in human adolescents and animal models. Neurosci Biobehav Rev 23 (1999) 993-1010
53. Laviola G., Macrì S., Morley-Fletcher S., and Adriani W. Risk-taking behavior in adolescent mice: Psycho-biological determinants and early epigenetic influence. Neurosci Biobehav Rev 27 (2003) 19-31
54. Levine S., Huchton D.M., Wiener S.G., and Rosenfeld P. Time course of the effect of maternal deprivation on the hypothalamic-pituitary-adrenal axis in the infant rat. Dev Psychobiol 24 (1991) 547-558
55. Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., and Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10 (1999) 1665-1669
56. Linnoila M., Virkkunen M., Schenin M., Nutila A., Rimon R., and Goodwin F.K. Low cerebrospinal fluid 5-hydroxyindolacetic acid concentrations differentiate impulsive from non-impulsive violent behaviour. Life Sci 33 (1983) 2609-2614
57. Liu Y.P., Wilkinson L.S., and Robbins T.W. Effects of acute and chronic buspirone on impulsive choice and efflux of 5-HT and dopamine in hippocampus, nucleus accumbens and prefrontal cortex. Psychopharmacology 173 (2004) 175-185
58. LoVerme J., La Rana G., Russo R., Calignano A., and Piomelli D. The search for the palmitoylethanolamide receptor. Life Sci 77 (2005) 1685-1698
59. Macrì S., and Laviola G. Single episode of maternal deprivation and adult depressive profile in mice: interaction with cannabinoid exposure during adolescence. Behav Brain Res 154 (2004) 231-238
60. Marco E.M., Perez-Alvarez L., Borcel E., Rubio M., Guaza C., Ambrosio E., et al. Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav Pharmacol 15 (2004) 21-27
61. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418 (2002) 530-534
62. Martín-Calderón J.L., Muñoz R.M., Villanua M.A., Del Arco I., Moreno J.L., Rodriguez De Fonseca F., et al. Characterization of the acute endocrine actions of (-)-11-hydroxy-Δ8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. Eur J Pharmacol 344 (1998) 77-86
63. McDonald J., Schleifer L., Richards J.B., and de Wit H. Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 28 (2003) 1356-1365
64. McGregor I.S., Issakidis C.N., and Prior G. Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacol Biochem Behav 53 (1996) 657-664
65. McLaughlin C.R., and Abood M.E. Developmental expression of cannabinoid receptor mRNA. Brain Res Dev Brain Res 76 (1993) 75-78
66. Olney J.W., Newcomer J.W., and Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33 (1999) 523-533
67. O'Shea M., Singh M.E., McGregor I.S., and Mallet P.E. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J Psychopharmacol 18 (2004) 502-508
68. Pagotto U., Marsicano G., Cota D., Lutz B., and Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27 (2006) 73-100
69. Patel S., and Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther (2006) 304-311
70. Patton G.C., Coffey C., Carlin J.B., Degenhardt L., Lynskey M., and Hall W. Cannabis use and mental health in young people: cohort study. BMJ 325 (2002) 1195-1198
71. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4 (2003) 873-884
72. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30 (1993) 672-679
73. Pryce C.R., Ruedi-Bettschen D., Dettling A.C., Weston A., Russig H., Ferger B., et al. Long-term effects of early-life environmental manipulations in rodents and primates: Potential animal models in depression research. Neurosci Biobehav Rev 29 (2005) 649-674
74. Ramos J.A., De Miguel R., Cebeira M., Hernández M., and Fernández-Ruiz J. Exposure to cannabinoids in the development of endogenous cannabinoid system. Neurotox Res 4 (2002) 363-372
75. Ramos J.A., Gonzalez S., Sagredo O., Gomez-Ruiz M., and Fernandez-Ruiz J. Therapeutic potential of the endocannabinoid system in the brain. Mini Rev Med Chem 5 (2005) 609-617
76. Ravinet Trillou C., Delgorge C., Menet C., Arnone M., and Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28 (2004) 640-648
77. Rodríguez De Fonseca F., Ramos J.A., Bonin A., and Fernández-Ruiz J.J. Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 4 (1993) 135-138
78. Sartorius A., Vollmayr B., Neumann-Haefelin C., Ende G., Hoehn M., and Henn F.A. Specific creatine rise in learned helplessness induced by electroconvulsive shock treatment. Neuroreport 14 (2003) 2199-2201
79. Schloss P., Mayser W., and Betz H. The putative rat choline transporter CHOT-1 transports creatine and is highly expressed in neural and muscle-rich tissues. Biochem Biophys Res Commun 198 (1994) 637-645
80. Schneider M., and Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28 (2003) 1760-1769
81. Schneider U., Leweke F.M., Mueller-Vahl K.R., and Emrich H.M. Cannabinoid/anandamide system and schizophrenia: is there evidence for association?. Pharmacopsychiatry 31 (1998) 110-113
82. Soubrié P. Reconciling the role of central serotonin neurones in human and animal behaviour. Behav Brain Sci 9 (1986) 319-364
83. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 24 (2000) 417-463
84. Sulcova E., Mechoulam R., and Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 59 (1998) 347-353
85. Vickers S.P., and Kennett G.A. Cannabinoids and the regulation of ingestive behaviour. Curr Drug Targets 6 (2005) 215-223
86. Viveros M.P., Llorente R., Moreno E., and Marco E.M. Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods. Behav Pharmacol 16 (2005) 353-362
87. Viveros M.P., Marco E.M., and File S.E. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81 (2005) 331-342
88. Williamson E.M., and Evans F.J. Cannabinoids in clinical practice. Drugs 60 (2000) 1303-1314
89. Witkin J.M., Tzavara E.T., and Nomikos G.G. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol 16 (2005) 315-331
90. Zimmerberg B., and Shartrand A.M. Temperature-dependent effects of maternal separation on growth, activity, and amphetamine sensitivity in the rat. Dev Psychobiol 25 (1992) 213-226